Approved: Daiichi Sanyo’s edoxaban

Tuesday, April 26, 2011 01:28 PM

Japan-based Daiichi Sankyo has received marketing approval by the Japanese Ministry of Health, Labor and Welfare for its anticoagulant edoxaban, according to Pharma Times.  

Edoxaban, a direct factor Xa inhibitor taken once a day has been approved for the prevention of venous thromboembolism (VTE) in patients with total knee and hip arthroplasty and hip fracture surgery.  It will be sold as Lixiana.

Joji Nakayama, Daiichi Sankyo chief executive, said the company thinks the drug “will make a great contribution to VTE prevention after major orthopedic surgery,” noting that Daiichi Sankyo is researching options for the drug for “several other indications.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs